← Eichor
Study identifier: NCT05610215 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy

Condition: Atrial Fibrillation · Cardiomyopathy, Hypertrophic · Radiofrequency Ablation  ·  Sponsor: China National Center for Cardiovascular Diseases

PhaseNA
Planned participants66
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.

This description comes directly from the study's public registry record.

Talk to the study team

Zhe Zheng, MD.PhD  ·  +86-010-88396051  ·  zhengzhe@fuwai.com

Yajie Tang, MD.PhD  ·  +8618813019554  ·  tangyajietangyajie@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05610215